SAN DIEGO, May 10, 2011 /PRNewswire/ -- Biocept, Inc., a privately-held laboratory testing company focused on the detection, enumeration and analysis of circulating tumor cells (CTCs) in cancer patients, today announced the publication of a paper describing the identification of different CTC phenotypes using its proprietary Cell Enrichment and Extraction (CEE™) platform. The paper, appearing in the Journal of Oncology and entitled "Detection of EPCAM-Negative and Cytokeratin-Negative CTCs in Peripheral Blood", supports a growing belief that there are many cancer patients with CTCs that don't meet the standard criteria by which a CTC is defined and, importantly, detected in current practice. The Biocept technology platform may allow more sensitive and comprehensive CTC tests for cancer patients.
David Hale, Executive Chairman of Biocept, said, "We are very excited with these results, as they support the potential of Biocept's CEE™ platform, not only to provide more sensitivity than current methods and detect more CTCs from the same blood sample, but also to derive more information about, and offer new insights into, a patient's cancer." He continued, "We are very optimistic that better treatment decisions, and, ultimately, better patient outcomes, will result."
CTCs are very rare in the blood of cancer patients, ranging from 1 to over a thousand in a standard 10 ml blood sample, which may contain 50-100 billion normal red or white blood cells. To be able to count or analyze CTCs, an enrichment process is necessary. Enrichment from blood is typically achieved using antibodies to EpCAM (Epithelial Cell Adhesion Molecule), a protein found on the surface of epithelial cells that enables them to bind to each other and to the extracellular matrix. CTCs are normally detected after capture using antibodies to cytokeratin (CK), an intracellular structural protein typically found in epithelial cel
|SOURCE Biocept, Inc.|
Copyright©2010 PR Newswire.
All rights reserved